Jun 23, 2026 06:40AM
Jun 17, 2026 04:19AM
May 12, 2026 07:00AM
May 5, 2026 04:21AM
May 4, 2026 04:30PM
May 4, 2026 04:30PM
May 4, 2026 10:14AM Citizens Reiterates Market Outperform Rating on Opus Genetics (IRD) Ahead of Trial Data Presentation
Apr 10, 2026 06:59AM
Mar 10, 2026 07:00AM
Feb 25, 2026 06:59AM
Feb 25, 2026 06:59AM
Jan 20, 2026 05:06AM
Jan 8, 2026 07:07AM
Jan 8, 2026 07:00AM Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
Nov 12, 2025 07:00AM
Nov 6, 2025 07:03AM
Nov 6, 2025 07:01AM
Nov 6, 2025 07:00AM
Nov 6, 2025 07:00AM
Oct 1, 2025 06:55AM
Sep 30, 2025 07:00AM Opus Genetics reports pediatric vision gains in gene therapy trial
Sep 30, 2025 07:00AM
Sep 4, 2025 08:00AM
Sep 4, 2025 08:00AM
Aug 18, 2025 08:01AM
Aug 18, 2025 08:00AM
Aug 13, 2025 04:30PM
Aug 5, 2025 08:00AM Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Jul 23, 2025 08:00AM
Jul 3, 2025 04:30PM
Jun 26, 2025 06:56AM
Jun 26, 2025 06:55AM
Jun 23, 2025 08:00AM
Jun 2, 2025 08:00AM
Jun 2, 2025 08:00AM Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Condi
May 15, 2025 08:00AM
May 12, 2025 08:00AM
May 6, 2025 08:03AM
May 6, 2025 08:00AM
May 5, 2025 08:00AM
Apr 15, 2025 10:36AM
Apr 8, 2025 08:01AM Opus Genetics (IRD) Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
Apr 8, 2025 08:00AM
Apr 2, 2025 08:00AM
Apr 1, 2025 06:51AM
Mar 31, 2025 08:20AM
Mar 21, 2025 05:03PM
Mar 21, 2025 09:30AM
Mar 21, 2025 09:12AM Opus Genetics (IRD) Prices $20M Share Offering, Concurrent Private Placement with Proceeds of Over $20M
Mar 21, 2025 09:11AM

324,017 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All